RxDoctor Payments Data

Fernando Scaglia

Clinical Genetics (M.D.) · Houston, TXNPI 1518047943

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $13,470 of the $15,849 with a category attached, or 85.0%. UCB, Inc. accounts for 61.6% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2024 at $9,578 and has fallen 82.3% since, to $1,693 in 2025.

$15,849in general payments, 2019–2025

Across 23 payments — averaging $689.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$10K
  • UCB SA$6K
  • Amicus Therapeutics, Inc.$31
  • Biomarin Pharmaceutical Inc.$23
$1,059,610in research payments, 2019–2025

Across 104 payments — averaging $10,189 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • PTC Therapeutics, Inc.$878K
  • Astellas Pharma Inc$158K
  • UCB Biosciences Inc.$16K
  • UCB SA$7K

What the payments were for

  • Consulting fees$13,47085%
  • Travel & lodging$1,76211%
  • Food & beverage$6174%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$15,849 in reported general payments places this provider in the 75th percentile of 37 clinical genetics (m.d.) providers in Texas.

See all clinical genetics (m.d.) providers in Texas →

Most prescribed under Part D

DrugClaimsCost to plans & patients
Miglustat22$257,814
Leucovorin Calcium11$756

Paid to pharmacies, not to this prescriber.

Other clinical genetics (m.d.) in Houston

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →